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1. Introduction 
There is immense scientific and medical interest in stem cells as a potential source material 
for regenerative medicine to replace or restore lost, damaged, or aging cells, tissues or 
organs (Mason and Dunnill 2008). The ideal stem cell candidate for regenerative medicine is 
a pluripotent stem cell that is easily obtainable, has a stable developmental potential even 
after prolonged culture, forms derivatives of all three embryonic germ layers from the 
progeny of a single cell and generates teratomas after injection into immunosuppressed 
mice (Mason and Dunnill 2008). Stem cell-based therapy has the potential to offer important 
new treatment options for insulin-dependent diabetes, Parkinson’s disease, cardiovascular, 
renal, musculoskeletal and retinal diseases and spinal cord diseases and trauma, among 
others. A critical question in this field is to establish which stem cells could be efficiently 
used clinically. 
In 1981, Martin and Evans achieved a milestone in stem cell biology with the derivation of 
mouse embryonic stem cells (ESCs; Evans and Kaufman 1981). The subsequent derivation of 
pluripotent human ESCs in 1998 by James Thomson (Thomson et al. 1998) and pluripotent 
stem cells from human primordial germ cells (Shamblott et al. 1998) ushered in a revolution 
in the field of regenerative medicine and tissue engineering. However, the destruction of 
human embryos to obtain ESCs and the need for therapeutic cloning to use them optimally 
made their clinical application highly controversial. In addition to ethical, legal and moral 
issues, ESCs have inherent limitations that must be overcome before their clinical use. One 
prime concern is the potential tumorigenicity of these cells in vivo. Although efforts to 
eliminate this possibility are underway, it remains a serious issue (Blum and Benvenisty 
2008; Fujikawa et al. 2005; Strulovici et al. 2007; Wu, Boyd, and Wood 2007). Other concerns 
are immune rejection (Drukker et al. 2002; Wobus and Boheler 2005), genetic instability and 
incomplete epigenetic reprogramming (Wobus and Boheler 2005). These concerns have 
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sparked interest within the scientific community in finding alternate sources of 
pluripotent/multipotent cells that have similar can as ESCs, but potentially circumvent the 
problems associated with these cells.  
The derivation of induced pluripotent stem cells (iPSCs) through the introduction of a 
small combination of transcription factors into terminally differentiated cells has raised 
the possibility of producing an alternate pluripotent stem cell source for use in 
regenerative medicine. Researchers at Kyoto University, Japan, were first to identify 
conditions that allowed mouse skin fibroblasts to be induced into pluripotency 
(Takahashi and Yamanaka 2006) and a year later human skin fibroblasts were also 
induced to pluripotency using this same approach (Takahashi, Okita et al. 2007; 
Takahashi, Tanabe et al. 2007; Yu et al. 2007). The iPSC technology has immense potential 
for clinical therapy as these cells avoid some ethical and moral issues associated with 
ESCs. The technology involves producing critical levels of proteins needed for 
pluripotency through introducing the genes into the target cells exogenously using viral 
vectors (Takahashi, Tanabe et al. 2007; Takahashi and Yamanaka 2006; Yu et al. 2007), 
adenoviral vectors (Stadtfeld et al. 2008; Okita et al. 2008) or non-viral plasmids (Okita et 
al. 2008) or introducing the actual recombinant proteins themselves into cells (Zhou et al. 
2009). Although initially there was concern over use of viral vectors integrating into the 
human genome and potentially inducing neoplastic changes, the use of alternate methods 
to deliver the pluripotency genes appears to circumvent that problem. Nonetheless, 
because there is genetic manipulation involved (Stadtfeld et al. 2010;  Stadtfeld and 
Hochedlinger 2010) and an increased risk of tumorigenicity (Nakagawa et al. 2008; Ben-
David and Benvenisty 2011; Kooreman and Wu 2010) extensive research has to be 
conducted before iPSCs are used clinically. Since iPSCs can be derived from patient-
specific cells, one potential benefit of these cells was a low or no risk of immune rejection. 
However, a recent finding suggests that this might not be true: In contrast to derivatives 
of ESCs, abnormal gene expression in iPSCs introduced into syngeneic mice in vivo 
induced T-cell-dependent immune responses, leading to immune infiltration and 
ultimately rejection of these cells (Zhao et al. 2011). This raises concerns for use of these 
cells in regenerative medicine. As with any new technology, there are a number of other 
hurdles to overcome before using iPSCs clinically, such as refractoriness of many adult 
cells to reprogramming, transient epigenetic memory of donor cells (Kim et al. 2010; Polo 
et al. 2010) and possible non-recurrent mutations. Despite these concerns, the tremendous 
progress and obvious potential of iPSCs over the past few years has overshadowed work 
on other potentially pluripotent stem cells, although some of these cells may ultimately 
offer therapeutic potential equal to that of iPSCs.  
2. Progress in regenerative medicine  
In 2010, two ESC-based human clinical trials were approved by the U. S. Food and Drug 
Administration, one initiated by Geron Corporation and the other by Advanced Cell 
Technology. Though the clinical trials are underway, there is concern that introducing stem 
cells that have not transformed into specialized cells into patients may pose the risk of 
teratoma formation. However, remarkable progress has been made in cell-based 
regenerative medicine over the past decade. The cell-therapy based industry now has an 
annual revenue of over a billion dollars and it is projected to rise to $5.1 billion by 2014 
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(Mason and Manzotti 2010). The initial research and monetary investment to develop stem-
cell based therapy is high. However, since the treatment involves transplantation of cells or 
tissues that can function normally for extended periods of time or even potentially for the 
remainder of a patient’s life, there is negligible need for ongoing treatment, rendering this 
modality of treatment potentially cost-effective (Mason and Dunnill 2008).  
The limitations and problems associated with iPSCs suggest that they may not offer the 
optimal solution for all aspects of regenerative medicine, raising the question of whether 
other stem cells may be preferable in some or potentially all regenerative medicine 
applications. Other stem cells that have received widespread attention in this regard include 
hematopoietic (HSC), mesenchymal and fetal cord blood stem cells. An adult allogenic stem 
cell source with developmental potential similar to ESCs and iPSCs would potentially be the 
most promising clinical approach if an optimal starting cell was found.  
Another stem cell that has been studied extensively for years and has recently been shown 
to have potential in regenerative medicine is the spermatogonial stem cell (SSC). This 
chapter focuses on recent developments in this field and the advantages and limitations of 
SSC use in regenerative medicine. We also briefly discuss other multipotent stem cells that 
may have significant clinical use. 
3. Spermatogonial Stem Cells 
In mammalian testes, SSCs are found along the basement membrane of seminiferous 
tubules. They produce the spermatogenic lineage, ensuring lifelong fertility of the 
individual. Like other stem cells, SSCs are undifferentiated and capable of self-renewal. 
While in the testicular microenvironment, they differentiate only into one specialized cell 
lineage, spermatozoa. However, when SSCs are isolated from the testis and placed into a 
different environment, they acquire or manifest pluripotency and differentiate into tissues 
belonging to all three embryonic germ layers (Kanatsu-Shinohara et al. 2008; Golestaneh et 
al. 2009; Simon et al. 2009; Ning et al. 2010). This property makes SSCs a powerful potential 
source of cells for regenerative therapy.  
3.1 Development and differentiation potential of SSCs  
In the embryo, the germ line arises from primordial germ cells (PGCs). PGCs are initially 
identifiable as a small cluster of cells in the proximal epiblast near the extra-embryonic 
ectoderm. This lineage differentiates under the influence of bone morphogenetic proteins 
(BMPs) and diverges from the somatic lineage in the late embryonic and early fetal stage 
(Lawson et al. 1999; Ying et al. 2000). Due to their extra-embryonal origin, they are not 
classified as belonging to a particular embryonic germ layer. Therefore, they are not 
subjected to many of the differentiation signals other stem cells receive (Lawson and Hage 
1994; Simon, Hess, and Cooke 2010); this may allow them to remain more undifferentiated 
than other stem cells. Following their initial development, PGCs subsequently migrate 
into the mesoderm, the endoderm (hindgut) and across the dorsal mesentery to reach the 
developing gonads at about 4-5 weeks of gestation in humans and 11-13 day post-coitum 
in rodents (Culty 2009). In the testis, PGCs then become mitotically quiescent until birth, 
and are called gonocytes. Shortly after birth, gonocytes resume mitosis and migrate to the 
basement membrane of seminiferous tubules, where they form SSCs and remain 
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throughout life. Thus, the embryological origin of SSCs is unique. This may facilitate their 
potential for differentiation into cell types of different germ cell layers and underlines 
their clinical potential for regenerative medicine. Furthermore, teratomas occur 
exclusively in gonads (Stevens 1964) and are of germ cell origin, and gene expression in 
early germ cells is very similar to ESCs (Zwaka and Thomson 2005; Simon, Hess, and 
Cooke 2010) , which emphasizes the broad developmental potential of SSCs. SSCs express 
genes such as POU domain class 5, transcription factor 1 (Pou5f1; Huang et al. 2009; 
Bhartiya et al.), Lin 28 (Zheng et al. 2009), undifferentiated embryonic cell transcription 
factor 1 (UTF-1) and Zinc finger protein 42 (Rex-1; Kristensen et al. 2008), which impart 
pluripotency. However, expression of another pluripotency gene, Nanog, is repressed in 
the testis by transformation related protein 53 (TRP53) and phosphatase and tensin 
homolog (PTEN). Both proteins belong to a critical signaling pathway preventing SSCs 
from being pluripotent while in the testis (Kuijk et al. 2009). Overall, this gene expression 
pattern suggests that SSCs have a gene profile similar to ESCs and thus are more 
undifferentiated than other adult stem cells. 
3.2 Current methods of isolation and propagation of SSCs with emphasis on human 
SSC isolation 
Spermatogonial stem cell constitute only 0.03% of the total germ cell population in rodent 
and human testis (Tegelenbosch and de Rooij 1993). Thus, their small numbers and the lack 
of specific markers are the main hurdles to their characterization. Nonetheless, significant 
progress has recently been made in the isolation and propagation of cells with SSCs 
properties from rodent (Dym et al. 2009; Guan et al. 2009; Kanatsu-Shinohara, Takehashi, 
and Shinohara 2008; Kubota, Avarbock, and Brinster 2004; Oatley and Brinster 2006, 2008; 
Ogawa et al. 2003; Hofmann et al. 2005; Kanatsu-Shinohara et al. 2010) and human testes 
(Conrad et al. 2008; Glaser et al. 2008; Golestaneh et al. 2009; Kossack et al. 2009; Zovoilis et 
al. 2008; Izadyar et al. 2011; He et al. 2009). Human testicular tissue is currently obtained 
from testicular biopsies (Izadyar et al. 2011; Kossack et al. 2009), orchiectomies (Izadyar et al. 
2011) and organ donors (Golestaneh et al. 2009). Testicular biopsies of approximately one 
gram can yield sufficient number of human SSCs for most clinical applications. Although 
our knowledge of mouse and human SSCs phenotype is still limited, studies suggest that 
human SSCs express proteins such as cluster of differentiation antigens 49f, 90 and 133 
(CD49f, CD90, and CD133, respectively), glial cell line-derived neurotrophic factor family 
receptor alpha 1 (GFRA1), G protein-coupled receptor 125 (GPR125), melanoma antigen 
family A 4 (MAGE4), promyelocytic leukemia zinc finger (PLZF) and stage-specific 
embryonic antigen-4 (SSEA-4; Costoya et al. 2004; Conrad et al. 2008; He et al. 2009; Izadyar 
et al. 2011). Using these markers in magnetic- or fluorescent-activated cell sorting, SSCs can 
be isolated with a high degree of purity (Gassei et al. 2009; Izadyar et al. 2011; Kokkinaki et 
al. 2009; Simon et al. 2010). Although there have been no definitive culture conditions for 
propagation of either mouse or human SSCs, culture systems established by different 
groups seem to be conducive for their propagation. At least in rodents, glial cell line-derived 
neurotrophic factor (GDNF) was found to be essential to maintain SSCs in an 
undifferentiated state in vivo and in vitro (Tyagi et al. 2009; Hofmann 2008; Sariola and 
Immonen 2008; Oatley, Avarbock, and Brinster 2007; Oatley et al. 2006; Naughton et al. 2006; 
Kubota, Avarbock, and Brinster 2004; Meng et al. 2000).  
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3.3 Spermatogonial stem cells are pluripotent 
In the testicular microenvironment, SSCs produce only the spermatogenic lineage, and the 
assumption was that this was their sole potential developmental fate. However, the 
iconoclastic finding of Kanatsu-Shinohara et al. (Kanatsu-Shinohara et al. 2004) 
demonstrated that neonatal murine SSCs produced ESC-like cells when isolated from the 
testis and grown for extended periods in ESC culture conditions. Although initial work was 
done with neonatal SSCs (Kanatsu-Shinohara et al. 2004; Kanatsu-Shinohara et al. 2008; 
Simon et al. 2009), subsequent work showed that adult murine SSCs (Glaser et al. 2008; 
Izadyar et al. 2008; Seandel et al. 2007; Guan et al. 2006) grown for 4-7 weeks in vitro also 
produced a low frequency of ESC-like colonies. These ESC-like cells can give rise to cell 
types derived from all three embryonic germ layers, and also produce teratomas when 
injected subcutaneously into nude mice. In addition, these ESC-like cells contribute to 
embryonic development when injected into blastocysts. ESC-like cells derived from SSCs 
have been termed multipotent germline stem cells (mGSCs) and these cells have been 
differentiated into many cell types. For example, two separate groups demonstrated that 
mGSCs could differentiate into mature cardiac and endothelial cells and that these cardiac 
cells were contractile and had electric potentials and ion channels (Baba et al. 2007; Guan et 
al. 2007). mGSCs derived from adult mouse SSCs could be differentiated into functional 
neurons and glia (Glaser et al. 2008; Streckfuss-Bomeke et al. 2009). Pluripotent stem cells 
were derived from adult mGSCs that not only could differentiate into a variety of cell types 
both in vivo and in vitro, but also showed germline transmission to the next generation 
when injected into blastocysts (Ko et al. 2009). Moreover, mGSCs have pluripotency 
characteristics similar to ESCs such as telomerase activity, telomere length and 
hypomethylation of pluripotency marker genes (Zechner et al. 2009)  
In recent years, several research groups reported methodologies for isolation and culture of 
human SSCs and also demonstrated that these cells were pluripotent/multipotent (Conrad 
et al. 2008; Golestaneh et al. 2009; Kossack et al. 2009; Dym et al. 2009; Izadyar et al. 2011). 
SSCs isolated from human testicular tissues and cultured for a week or more spontaneously 
produced ESC-like small colonies, which were then transferred into ESC media and cultured 
for about 4 weeks to get sufficient numbers of ESC-like colonies and these ESC-like cells 
could then be differentiated into specific cell types. These results indicate that human SSCs 
have the potential to be used as an alternate source of pluripotent stem cells in regenerative 
cell therapy, without the ethical concerns of ESC and the concerns involving exogenous gene 
introduction in iPSCs.  
4. Direct differentiation of spermatogonial stem cells 
4.1 Epithelial-mesenchymal interactions 
Epithelial-mesenchymal interactions are critical for organogenesis in many organs such as 
lung, prostate, mammary gland, liver, pancreas and salivary glands (Grobstein 1953). 
Mesenchyme, which is undifferentiated connective tissue, signals to the epithelium to 
induce epithelial morphogenesis and cytodifferentiation in a wide variety of organs. The 
central role of epithelial-mesenchymal interactions in organ development was postulated 
initially by Pander and later experimentally demonstrated by Spemann and Saunders (in 
Simon, Hess, and Cooke 2010). 
www.intechopen.com
 
Tissue Regeneration – From Basic Biology to Clinical Application 
 
208 
Classical tissue recombination experiments conducted by Cunha and coworkers with 
reproductive tissue demonstrated that the mesenchyme dictates the fate of the epithelium in 
various reproductive tissues. The urogenital sinus is an ambisexual fetal organ that gives 
rise to the prostate in males and a portion of the vagina in females. Under the influence of 
androgen, urogenital sinus mesenchyme (UGM) induces urogenital sinus epithelium (UGE) 
to differentiate into prostatic epithelium and UGM also regulates epithelial ductal 
morphogenesis and cytodifferentiation in prostate. UGM also instructively induces prostatic 
morphogenesis in other epithelia (Cunha et al. 1983; Cunha, Lung, and Reese 1980; Cunha, 
Sekkingstad, and Meloy 1983). For example, UGM instructively induces adult bladder 
epithelium to form prostatic epithelium in tissue recombinants in vivo (Cunha et al. 1983). 
Similarly, neonatal uterine mesenchyme instructively induces neonatal vaginal epithelium 
to form uterine epithelium (Cunha 1976).  
4.1.1 Potential signaling pathways involved in epithelial-mesenchymal interactions 
Although mesenchymal paracrine signaling is essential for determining epithelial fate, the 
specific signaling pathway(s) involved in this phenomenon remain unclear. Some possible 
signaling molecules are Wnt7a (Miller and Sassoon 1998), hepatocyte growth factor (HGF) 
and fibroblast growth factor (FGF) family molecule(s) in the uterus (Chen, Spencer, and 
Bazer 2000, 2000), HGF and FGF family molecule(s) for lung organogenesis (Ohmichi et al. 
1998) (for review see Kumar et al. 2005,) and FGF and Wnt and Hedgehog signaling in the 
prostate (for review see Thomson, Cunha, and Marker 2008; Cunha, Cooke, and Kurita 2004; 
Lin and Wang, 2010; Taylor et al. 2009).  
4.1.2 Mesenchyme dictates the fate of stem cell differentiation 
The demonstrations that epithelial-mesenchymal interactions are essential for organogenesis 
also triggered interest in using this approach in regenerative therapy. ESCs were 
differentiated into prostatic epithelium by recombining mouse UGM and human ESCs and 
growing these tissue recombinations in vivo (Taylor et al. 2006). Using a similar 
methodology (Oottamasathien et al. 2007; Anumanthan et al. 2008), human ESCs or bone 
marrow-derived mesenchymal stem cells have been differentiated into bladder epithelium 
by exposing these cells to the inductive influence of bladder mesenchyme in a tissue 
recombinant. More recently, Taylor et al. demonstrated that stroma could induce adult stem 
cells to express dual phenotypes (Taylor et al. 2009). Prostatic stroma induced putative 
mammary epithelial stem cells to generate glandular epithelia expressing both prostatic and 
mammary markers. These results demonstrate that the mesenchyme can instructively direct 
the differentiation of ESCs or other stem cells into a specific cell fate. 
4.2 Spermatogonial stem cells differentiate into tissues of all three embryonic germ 
layers in response to instructive inducers 
Based on demonstrations of the importance of the stem cell niche (Tyagi et al. 2009;  de Rooij 
2009; Hess et al. 2006; Simon et al. 2010; Oatley, Racicot, and Oatley 2010), the pluripotential 
nature of SSCs and the instructive potential of various mesenchymes, we postulated and 
subsequently demonstrated that neonatal mouse SSCs could directly differentiate into 
prostatic, uterine and skin epithelium (Simon et al. 2009) when recombined with the 
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appropriate mesenchyme and grafted in vivo (Fig. 1). To track cell lineages derived from 
SSCs in tissue recombinations and verify that these cells were undergoing differentiation, wt 
transgenic C57BL/6 mice expressing enhanced green fluorescent protein (GFP) ubiquitously 
were used. For example, UGM derived from wild-type mice (wt-UGM) were recombined 
with SSCs derived from mice expressing GFP (G-SSC) and grafted under the renal capsule 
of syngeneic male hosts. After 4 weeks of growth, the epithelium in these, wt-UGM + G-
SSC, tissue recombinants expressed NKX3.1, a prostatic epithelial marker and androgen 
receptor but not germ cell nuclear antigen 1 (GCNA1), a germ cell marker. The tissue 
recombinants had an epithelium that stained intensely for GFP (Fig. 1A), indicating that it 
was of SSC origin, while stromal cells lacked GFP staining.  Similarly uterine mesenchyme 
(UtM) from mice expressing GFP (G-UtM) recombined with SSCs derived from wt-mice (wt-
SSC) differentiated into uterine epithelium that expressed cytokeratin 8 (CK8), estrogen 
receptor–alpha and progesterone receptor. In these G-UtM + wt-SSC tissue recombinants, 
stromal cells strongly expressed GFP, while epithelium did not, indicating that the 
epithelium was of SSC origin (Fig. 1B). This approach provides a method to directly 
differentiate SSCs into specific cell types from all three embryonic germ layers without the 
extended culture period needed in vitro to produce ESC-like cells that can subsequently 
differentiate into various derivatives. 
  
Fig. 1. Differentiation of SSCs into prostatic and uterine epithelium. A) Urogenital sinus 
mesenchyme (UGM) from wild-type (wt) mice was recombined with SSCs derived from 
mice that expressed enhanced green fluorescent protein (G) ubiquitously and was grafted 
under the renal capsule of syngeneic male hosts. After 4 weeks of in vivo growth, the wt-
UGM + G-SSC tissue recombinants formed prostatic epithelium (E) that was of SSC origin 
expressing GFP and androgen receptor (AR, red nuclei). B) Uterine mesenchyme (UtM) 
from GFP mice was recombined with SSCs derived from wt mice and grafted under the 
renal capsule of syngeneic female hosts. After 4 weeks of growth, the G-UtM + wt-SSC 
tissue recombinants formed uterine epithelium (E) that was of SSC origin expressing 
cytokeratin 8 (CK8). Stromal cells (S) express GFP but E does not. SSCs do not express AR or 
CK8. 
When SSCs were mixed with mammary epithelial cells and grafted into the mammary fat 
pad in vivo, SSCs differentiated into mammary epithelial cells, but the stem cells alone 
could not be differentiated into mammary cells (Boulanger et al. 2007). This suggests that the 
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inductive potential of the adult mammary fat pad might not be sufficient for directing the 
differentiation of SSCs into mammary epithelial cells. This is a potential hurdle for the use of 
this methodology, as the inductive mesenchyme for most of the organs is present during 
fetal life, and as they transition to form adult stromal cells they might lose this ability to 
instructively induce other epithelia. However, a recent study demonstrated direct 
differentiation of SSCs into hematopoietic cells (Ning et al., 2010). When SSCs were injected 
into the bone marrow of adult female mice, these mice had Y chromosome positive-cells that 
had phenotypical and functional characteristics of hematopoietic cells both in vivo and in 
vitro, emphasizing both the pluripotential nature of SSCs and that the microenvironment 
even in adult organs plays a decisive role in directing the differentiation of SSCs.  
As discussed earlier, our understanding of the mechanistic basis of epithelial-mesenchymal 
interactions is fragmentary. Fetal mesenchymes are potent instructive inducers, and one of 
the challenges for using this methodology will be to determine whether or not adult stroma 
is capable of similar instructive inductions. Once we are able to dissect out the molecular 
mechanisms used by mesenchyme to instructively induce epithelial morphogenesis, it will 
be feasible to expose SSCs to the inductive signals produced by these tissues in vitro, on 
artificial scaffolds or some other arrangement. Another major limitation of this methodology 
is that it is inapplicable to tissues that do not involve epithelial-mesenchymal interactions 
during development. However, the direct differentiation of SSCs into hematopoietic cells 
(Ning et al., 2010) discussed above suggests that SSCs will differentiate into a specific tissue 
type when exposed to an appropriate microenvironment, even in the absence of epithelial-
mesenchymal interactions. Thus further research is necessary to determine both the full 
developmental potential of SSCs and the most appropriate methodology for inducing 
specific cell types, but SSCs appear to have great potential in this regard.  
4.3 Mechanism of differentiation of spermatogonial stem cells into other cell types 
The mechanism of differentiation of SSCs into other cell types under the influence of 
instructive inducers is poorly understood. One possibility is that in response to an inductive 
mesenchyme, the SSCs de-differentiate into ESC-like cells (as has been reported in vitro), 
and then subsequently differentiate into a new epithelia. However, our preliminary studies 
indicate that SSCs may not undergo a de-differentiation step in the presence of an inductive 
mesenchyme, but instead may differentiate directly from SSCs to another epithelial type 
without going through an intermediate ESC-like cell stage. Shinohara and coworkers 
(Kanatsu-Shinohara et al. 2008) demonstrated that a single spermatogonial stem cell could 
produce an embryonic stem-like line that was multipotent and germline stem cells that were 
committed to spermatogenesis, indicating that all SSCs may be capable of becoming 
pluripotent. This is supported by other studies (Ko et al. 2009). Conversely, Izadyar et al. 
suggested that there are two distinct populations of SSCs, one that is OCT4+ and c-KIT- that 
gives rise to multipotent cells and another that is OCT4+ and c-KIT+ that gives rise to the 
spermatogenic lineage (Izadyar et al. 2008). A definitive elucidation of how SSCs 
differentiate into other tissue types, as well as definitively establishing whether all SSCs or a 
specific subpopulation can be converted into other tissues, will be an essential prerequisite 
for successful use of this approach in a clinical setting. Nonetheless, SSCs can be 
differentiated into specific cell types using different approaches and be a potential source for 
pluripotent cells for stem cell-based therapy (Fig. 2). 
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Fig. 2. Potential use of spermatogonial stem cells (SSCs) in regenerative medicine. 
Spermatogonia in the murine seminiferous tubule expressing PLZF, a SSC marker. SSCs are 
isolated from the testis using magnetic- or fluorescent-activated cell sorting. Some of the 
possible methods of differentiating SSCs into specific cell types are 1) Long-term culture of 
SSCs, selection for cells that form embryonic stem cell-like colonies and subsequent culture 
and differentiation of these pluripotent cells into specific cell types. 2) Recombination of 
SSCs with instructive inducers to directly differentiate SSCs into specific epithelial cell 
types; 3) Direct injection to a specific site of injury or specific microenvironment. Since SSCs 
are unspecialized, they could home and respond to signals in the new microenvironment 
and differentiate into cells of all three embryonic germ layers. 
5. Advantages and limitations of SSCs over other pluripotent stem cell 
sources 
SSCs, as well as other adult derived stem cells, may be safer to use therapeutically than 
ESCs or iPSCs. Since SSCs are more differentiated than ESCs, they are less likely to induce 
teratomas (Kossack et al. 2009). However, the risk of malignant transformation cannot be 
totally rejected since SSCs are relatively more undifferentiated than other adult stem cells. 
This type of problem is illustrated by the formation of brain tumors from donor-derived 
cells in patients who received fetal stem cells for treatment of ataxia-telangiectasia 
(Amariglio et al. 2009), emphasizing that tumorigenicity is the biggest impediment for the 
use of pluripotent stem cells in cell therapy. Another obstacle is the immunogenicity of SSCs 
and potential risk of rejection of the cells (Dressel et al. 2009). But immune rejection of 
autologous or allogenic stem cell transplants can be minimized by routine 
immunosuppression treatments as is used for organ transplantation. Another possible 
alternative is genetic manipulation of stem cells and elimination of genes responsible for 
immune rejection (Wobus and Boheler 2005).  
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6. Alternate sources of stem cells for use in regenerative medicine 
The use of stem cells in regenerative medicine began when bone marrow cells were 
transplanted to treat acute leukemia (Thomas et al. 1959), and presently HSC therapy is the 
only stem cell therapy widely used clinically (Helmy et al. 2010). There is growing evidence 
that HSCs are plastic—and can give rise to tissues other than those of the blood system, e.g., 
liver cells (Lagasse et al. 2000). Another readily available source is mesenchymal stem cells 
that can be isolated from adult tissue, fetal tissue and umbilical cord blood. These cells can 
differentiate into osteoblasts, chondrocytes and adipocytes (Friedenstein et al. 1974; 
Pittenger et al. 1999) neurons (Cho et al. 2005), astrocytes (Kopen, Prockop, and Phinney 
1999) and hepatocyte-like cells (Petersen et al. 1999). The use of adipose stem cells as a 
source for cell therapy is increasing rapidly as methods of isolation and culture are 
standardized; subcutaneous depots are easily accessible, replenishable and are often 
abundant. Adult stem cells derived from adipose tissues can differentiate in vitro into many 
cell types including adipocyte, chondrocyte, endothelial, epithelial, hematopoietic support, 
hepatocyte, neuronal, myogenic, and osteoblast lineages (Gimble and Guilak 2003; 
Halvorsen et al. 2001; Safford et al. 2002; Zuk et al. 2001). Fetal stem cells are self-renewing 
cells located in various types of fetal tissue, including umbilical cord blood, umbilical cord 
matrix, fetal blood and the amniotic membrane (Reinisch and Strunk 2009; Jager et al. 2009; 
Zeddou et al., 2010). Umbilical cord blood contain multiple populations of stem cells that 
can be effective in treating many diseases such as hematological malignancies, 
hemoglobinopathies, metabolic disorders and the greatest advantage of these cells is 
decreased immune rejection (Liao et al., 2011).  
 
Stem Cells Advantages Major limitations 







Induced pluripotent cells Pluripotent 
Initial source of cells are easy 
to obtain 
No ethical or moral concerns 
Indefinite self-renewal 
potential 









No ethical or moral concerns 
Relatively easy to obtain 
Less tumorigenic potential 
Relatively small numbers  
Difficult to maintain in 
cultures 
 
Fetal stem cells (Fetal 
cord blood, umbilical 
cord tissue) 





and self-renewal potential 
Adult stem cells 
(hematopoietic,  
mesenchymal, adipose) 
Easy to obtain 
Reduced risk of 
tumorigenicity 
Restricted differentiation 
and self-renewal potential 
Table 1. Potential advantages and limitations of stem cells in regenerative medicine 
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Among pluripotent/multipotent stem cells (Table 1), spermatogonial stem cells have great 
potential and some unique advantages. Despite their promise, numerous hurdles must be 
overcome before clinical use of SSCs. The small population of SSCs in the testis and the 
difficulty in propagating and maintaining them in culture is one major hurdle. The 
methodology proposed here is promising but extensive work is needed before its 
application in regenerative medicine.  
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